Skip to main content
SpringerLink
Log in

Alternating Treatment with S-1 Plus Low-Dose Cisplatin and S-1 Alone for Advanced Gastric Cancer

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

The aim of this study was to investigate the efficacy and safety of an alternating regimen of S-1 plus low-dose cisplatin and S-1 alone as adjuvant therapy in patients with advanced gastric cancer.

Patients and Methods

The study group comprised 100 patients with stage IIIA, stage IIIB, or stage IV. Patients postoperatively received three 5-week cycles of chemotherapy. In the first cycle, S-1 (80 mg/m2) was given daily for 3 weeks, followed by 2 weeks of rest, and low-dose cisplatin (10 mg) was given on days 1 to 5 and 8 to 12. In the second and third 5-week cycles, S-1 alone was given. The primary endpoints were median survival time, and survival at 1 and 3 years. Secondary endpoints were safety and overall response rates.

Results

Median survival time was 18 months in stage IV and 32 months in stage IIIB. The rates of survival at 1 and 3 years were 68.7% and 30.6% in stage IV, 100% and 68.4% in stage IIIA, and 100% and 46.6% in stage IIIB, respectively. Adverse events of grade 3 or 4 occurred in 14% of the patients. The overall response rate of target lesions was 54%.

Conclusion

Our regimen is effective and safe for adjuvant therapy in patients with curatively resected stage III gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Macdonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533–36.

    PubMed  CAS  Google Scholar 

  2. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57.

    PubMed  CAS  Google Scholar 

  3. Ohtsu A, Shimada Y, Shirako K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54–59.

    Article  PubMed  CAS  Google Scholar 

  4. Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310–17.

    PubMed  CAS  Google Scholar 

  5. Wilke H, Preusser P, Fink U, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer-a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 1990; 8: 65–70.

    Article  PubMed  CAS  Google Scholar 

  6. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609–16.

    PubMed  CAS  Google Scholar 

  7. Cutsem EV, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991–97.

    Article  PubMed  Google Scholar 

  8. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666–73.

    Article  PubMed  Google Scholar 

  9. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36–46.

    Article  PubMed  CAS  Google Scholar 

  10. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215–21.

    Article  PubMed  CAS  Google Scholar 

  11. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30.

    Article  PubMed  CAS  Google Scholar 

  12. Cummingham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.

    Article  Google Scholar 

  13. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810–20.

    Article  PubMed  CAS  Google Scholar 

  14. Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548–57.

    Article  PubMed  CAS  Google Scholar 

  15. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57: 202–10.

    Article  PubMed  CAS  Google Scholar 

  16. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715–20.

    Article  PubMed  CAS  Google Scholar 

  17. Koizumi W, Kurihara M, Nakao S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58: 191–97.

    Article  PubMed  CAS  Google Scholar 

  18. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207–12.

    Article  PubMed  CAS  Google Scholar 

  19. Ajani JA, Lee FC, Singh DA, et al. MultiCentre phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 663–67.

    Article  PubMed  CAS  Google Scholar 

  20. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric cancer 1998; 1: 10–24.

    Article  PubMed  Google Scholar 

  21. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063–9.

    Article  PubMed  CAS  Google Scholar 

  22. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: A randomized trial. Lancet 1999; 354: 273–7.

    Article  PubMed  CAS  Google Scholar 

  23. Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: Update of a meta-analysis. Int J Clin Oncol. 2009 Apr;14(2):85–9.

    Article  PubMed  CAS  Google Scholar 

  24. Hyodo I, Nishina T, Moriwaki T, et al. A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 2003; 39: 2328–33.

    Article  PubMed  CAS  Google Scholar 

  25. Iwase H, Shimada M, Tsuzuki T, et al. A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 2005; 25: 1297–1302.

    PubMed  CAS  Google Scholar 

  26. Tsuji A, Shima Y, Morita S, et al. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: A retrospective study. Anticancer Res 2008; 28: 1433–38.

    PubMed  CAS  Google Scholar 

  27. Chang HY, Sung HN, Yong IK, et al. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. World J Surg 1999; 23: 492–98.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Shin-Tokyo Hospital, 473-1 Nemoto, Matsudo, Chiba, Japan

    Kazuhito Mita, Hideto Ito, Masato Fukumoto, Ryo Murabayashi, Kazuya Koizumi, Takashi Hayashi, Hiroyuki Kikuchi & Tadashi Kagaya

Authors
  1. Kazuhito Mita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideto Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masato Fukumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryo Murabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuya Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tadashi Kagaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhito Mita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mita, K., Ito, H., Fukumoto, M. et al. Alternating Treatment with S-1 Plus Low-Dose Cisplatin and S-1 Alone for Advanced Gastric Cancer. J Gastrointest Surg 15, 791–796 (2011). https://doi.org/10.1007/s11605-011-1476-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-011-1476-z

Keywords

Search

Navigation